H Sunpath1,2, T J Hatlen3, M-Y S Moosa2, R A Murphy4, M Siedner5, K Naidoo1,6. 1. Centre for AIDS Program of Research, University of KwaZulu-Natal, Durban. 2. Infectious Diseases Unit, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa. 3. Division of HIV, Lundquist Institute for Biomedical Innovation at Harbor-University of California Los Angeles Medical Center, Torrance, CA. 4. Division of Infectious Diseases, Lundquist Institute for Biomedical Innovation at Harbor-University of California Los Angeles Medical Center, Torrance, CA. 5. Massachusetts General Hospital, Boston, MA, USA. 6. HIV-TB Pathogenesis and Treatment Research Unit, Medical Research Council-Centre for the AIDS Programme of Research in South Africa, Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa.
Abstract
INTRODUCTION: Delayed identification and response to virologic failure in case of first-line antiretroviral therapy (ART) in resource-limited settings is a threat to the health of HIV-infected patients. There is a need for the implementation of an effective, standardized response pathway in the public sector. DISCUSSION: We evaluated published cohorts describing virologic failure on first-line ART. We focused on gaps in the detection and management of treatment failure, and posited ways to close these gaps, keeping in mind scalability and standardization. Specific shortcomings repeatedly recorded included early loss to follow-up (>20%) after recognized first-line ART virologic failure; frequent delays in confirmatory viral load testing; and excessive time between the confirmation of first-line ART failure and initiation of second-line ART, which exceeded 1 year in some cases. Strategies emphasizing patient tracing, resistance testing, drug concentration monitoring, adherence interventions, and streamlined response pathways for those failing therapy are further discussed. CONCLUSION: Comprehensive, evidence-based, clinical operational plans must be devised based on findings from existing research and further tested through implementation science research. Until this standard of evidence is available and implemented, high rates of losses from delays in appropriate switch to second-line ART will remain unacceptably common and a threat to the success of global HIV treatment programs.
INTRODUCTION: Delayed identification and response to virologic failure in case of first-line antiretroviral therapy (ART) in resource-limited settings is a threat to the health of HIV-infected patients. There is a need for the implementation of an effective, standardized response pathway in the public sector. DISCUSSION: We evaluated published cohorts describing virologic failure on first-line ART. We focused on gaps in the detection and management of treatment failure, and posited ways to close these gaps, keeping in mind scalability and standardization. Specific shortcomings repeatedly recorded included early loss to follow-up (>20%) after recognized first-line ART virologic failure; frequent delays in confirmatory viral load testing; and excessive time between the confirmation of first-line ART failure and initiation of second-line ART, which exceeded 1 year in some cases. Strategies emphasizing patient tracing, resistance testing, drug concentration monitoring, adherence interventions, and streamlined response pathways for those failing therapy are further discussed. CONCLUSION: Comprehensive, evidence-based, clinical operational plans must be devised based on findings from existing research and further tested through implementation science research. Until this standard of evidence is available and implemented, high rates of losses from delays in appropriate switch to second-line ART will remain unacceptably common and a threat to the success of global HIV treatment programs.
Authors: H Sunpath; T J Hatlen; K K Naidu; P Msimango; R N Adams; M-Y S Moosa; V C Marconi; R A Murphy; R T Gandhi; S Pillay; M Siedner; K Naidoo Journal: Public Health Action Date: 2018-12-21
Authors: Matthew P Fox; Sophie J S Pascoe; Amy N Huber; Joshua Murphy; Mokgadi Phokojoe; Marelize Gorgens; Sydney Rosen; David Wilson; Yogan Pillay; Nicole Fraser-Hurt Journal: Trop Med Int Health Date: 2018-10-24 Impact factor: 2.622
Authors: Vincent C Marconi; Henry Sunpath; Zhigang Lu; Michelle Gordon; Kofi Koranteng-Apeagyei; Jane Hampton; Steve Carpenter; Janet Giddy; Douglas Ross; Helga Holst; Elena Losina; Bruce D Walker; Daniel R Kuritzkes Journal: Clin Infect Dis Date: 2008-05-15 Impact factor: 9.079
Authors: Kiran Jobanputra; Lucy Anne Parker; Charles Azih; Velephi Okello; Gugu Maphalala; Bernard Kershberger; Mohammed Khogali; Johnny Lujan; Annick Antierens; Roger Teck; Tom Ellman; Rose Kosgei; Tony Reid Journal: PLoS One Date: 2015-02-19 Impact factor: 3.240
Authors: Victor Ssempijja; Gertrude Nakigozi; Larry Chang; Ron Gray; Maria Wawer; Anthony Ndyanabo; Jingo Kasule; David Serwadda; Barbara Castelnuovo; Anja Van't Hoog; Steven James Reynolds Journal: BMC Infect Dis Date: 2017-08-22 Impact factor: 3.090
Authors: Diane Havlir; Shahin Lockman; Helen Ayles; Joseph Larmarange; Gabriel Chamie; Tendani Gaolathe; Collins Iwuji; Sarah Fidler; Moses Kamya; Sian Floyd; Janet Moore; Richard Hayes; Maya Petersen; Francois Dabis Journal: J Int AIDS Soc Date: 2020-02 Impact factor: 5.396